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Abstract 
Background: Methamphetamine (METH) is an illicit psychostimulant 
that is widely abused in the world. Several lines of evidence suggest 
that chronic METH abuse leads to neurodegenerative changes in the 
human brain. These include damage to dopamine and serotonin axons, 
loss of gray matter accompanied by hypertrophy of the white matter, 
and microgliosis in different brain areas. 
Methods: Magnetic resonance spectroscopy measures of N-acetyl 
aspartate (NAA), Creatine (Cre), Choline (Cho), Myo-inositol (Ml), 
were obtained in the dopamine circuit (Ventral Tegmental Area, 
Nucleus Accumbens, Substantia nigra, Striatum, Frontal Cortex, 
Hippocampus) of the brain in participants in 30 abstinent 
methamphetamine-addicted people with psychosis (METHp+), and 10 
healthy controls (HCs) (age ranges of 18 to 50 years old). Psychotic 
symptoms were assessed with the positive and negative Syndrome scale 
(PANSS) and analyzed using a five-factor model. All participants were 
also assessed for physical and mental illnesses as well as recent 
substance use. 
Results: The METHp+group displayed robust alteration in basic 
metabolite concentration levels (NAA, cho, Cr, mI, and GLX) relative 
to HCs. This suggests that cellular metabolism is altered in both 
conditions but in METHp+group is seeing more dramatic changes. 
Significant decrease in the concentration of NAA metabolites (mean of 
18.56) in the methamphetamine group with high psychological 
symptoms (mean of 111.9) in the studied areas compared to the control 
group which is a neurotransmitter and biomarker, indicates chronic 
neurological degeneration in the test areas and its relationship with the 
incidence of mental disorders in these individuals (Pvalue<0.01). 
Conclusions: These data support the assumption that cellular 
abnormalities differ between methamphetamine addiction psychosis 
and healthy controls people despite not different in normal imaging 
acquisition. 
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Introduction 
Methamphetamine (METH) abuse is a disorder 
characterized by compulsive METH-craving and consumption 
despite an apparent awareness of serious negative 
consequences.1 METH use has been linked to the emergence of 
psychotic symptoms as well as morphological, functional, and 
neurochemical abnormalities in multiple brain regions.2 
Multiple lines of preclinical evidence suggest that chronic 
methamphetamine use may cause a series of cellular effects 
that are local to dopamine and serotonin synapses, and 
eventually, lead to neurotoxic damages resulting from the 
pathological mechanisms that include oxidative stress and 
mitochondrial dysfunction.3 These cellular changes may be 
associated with macroscopic structural abnormalities of both 
cortical and subcortical brain regions in methamphetamine-
dependent subjects.4 Acute administration of MA increases 
extracellular DA levels via the reverse transport of DA and also 
by the displacement of DA from vesicular stores.5 The 
displaced monoamine is then oxidized and converted to 
reactive oxygen species which ultimately contribute to necrotic 
cell death.6 The lipophilic nature of MA allows it to penetrate 
cellular membranes and disrupt the electrochemical gradient of 
key organelles such as mitochondria resulting in neurotoxicity 
driven by apoptosis.7 The monoamines released due to the 
presence of methamphetamine act on the major dopaminergic, 
noradrenergic, and serotonergic pathways of the brain. In the 
case of dopamine, methamphetamine activates the mesolimbic, 
mesocortical circuit, and the nigrostriatal pathways, which have 
been related to the euphoric effects observed immediately after 
the ingestion of the drug.8 Due to its structural similarity, 
methamphetamine substitutes for the dopamine transporter 
(DAT), noradrenaline transporter (NET), serotonin transporter 
(SERT), and vesicular monoamine transporter-2 (VMAT-2) 
and reverses their endogenous function, thereby redistributing 
monoamines from storage vesicles into the cytosol.9 This 
process results in the release of dopamine, noradrenaline, and 
serotonin into the synapse, which then stimulates postsynaptic 
monoamine receptors.10 Methamphetamine also attenuates the 
metabolism of monoamines by inhibiting monoamine oxidase 
further enabling the buildup of excess monoamines in the 
synapse.11 Human positron emission tomography (PET) studies 
have reported a significant reduction of dopamine transporter 
density in methamphetamine users and that the reduction 
observed in methamphetamine users is associated with 
psychomotor impairment. Recently, we have also found that 
the dopamine transporter density in methamphetamine users is 
inversely related to the length of methamphetamine use and the 
magnitude of psychiatric symptoms, including psychotic 
symptoms.12 In addition, it has been hypothesized that brain 
damage resulting from methamphetamine abuse outlives the 
duration of drug use and can be documented objectively by 
structural and chemical changes in abstinent 
methamphetamine-dependent subjects. Specifically, enlarged 
brain volume was observed in recently abstinent (4 months) 
methamphetamine users and relatively normal volume with 
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longer than 20 months of abstinence.13 MRS of N-
acetylaspartate (NAA), an axonal marker in white matter and a 
neuronal marker in gray matter, indicates a significant decrease 
in NAA levels in abstinent methamphetamine-dependent 
subjects whose abstinence periods were between 8 to 20 weeks, 
consistent with neuronal and/or axonal damage which lasts 
beyond the immediate period of drug abuse. Furthermore, 
reduction of Glx (glutamine plus glutamate), in the frontal 
brain was observed in early abstinent methamphetamine users, 
followed by relatively normal Glx concentration after 2 months 
of abstinent. Structural abnormalities in the corpus callosum 
were also observed in methamphetamine abusers who were 
abstinent for a longer time (mean=21 months). White matter 
abnormalities in amphetamine abusers have now been reported 
more often than gray matter abnormalities. A single MRI 
session can incorporate several sequences that assess several 
tissue parameters (volumes of gray and white matter, T1, T2, 
DTI, iron measures, etc), and also collect functional 
information.14 Exploration of such multimodal datasets will 
increase our understanding of both the underlying 
pathophysiology and the techniques themselves.15 
Understanding of the technical aspects of brain imaging tools 
that we use on clinical patients must progress towards 
increasing the specificity of measures or combinations of 
measures to further the twin goals of using brain imaging to 
inform both medication development and clinical decision 
making.6,7 The psychiatric research interview for substance and 
mental disorders (PRISM), which employs the diagnostic and 
statistical manual of mental disorders (DSM-IV) criteria for 
psychotic disorders, was utilized to discriminate between 
substance-induced and primary psychosis. Of note, a diagnosis 
of primary psychosis was made if there was “no evidence of 
heavy substance uses or withdrawal, when psychotic symptoms 
persisted for at least 4 weeks in the absence of heavy substance 
use, or when psychotic symptoms preceded the onset of heavy 
use”. Parental substance abuse, drug dependence (rather than 
abuse or use), and visual hallucinations were predictive of a 
substance-induced psychosis. Additionally, persons with 
substance-induced psychosis had lower positive and negative 
syndrome scale (PANSS) scores, greater awareness of 
psychotic symptoms, and were more likely to have suicidal 
ideation.16 Clinical symptoms of MA-induced psychosis 
include paranoia, delusions, and hallucinations. Psychosis 
occurs at least intermittently in a significant proportion of MA 
users, with wide variation in the severity and clinical course of 
symptoms.17 Methamphetamine-associated psychiatric 
impairment may occur in several domains of cognitive, 
intellectual, or affective. Psychiatric impairment appears to 
correlate with duration of use as well as total and peak amounts 
of MA absorbed. Neurocognitive deficits associated with 
chronic MA use include impairments in episodic memory, 
executive functions, and psychomotor tasks related to 
frontostriatal and limbic circuits. Methamphetamine use may 
also be associated with deficits in attention, memory, and 
language. Neurocognitive impairment may persist for nine 
months or longer following cessation of MA use, but a 
recovery in dopamine transporter activity and improvement in 
cognitive functioning is possible with sustained 
abstinence.18,19,20 Psychiatric symptoms have been well-
documented in MA users. Anxiety, depression, insomnia, and 
psychosis are among the most commonly reported symptoms 
associated with MA dependence, and individuals presenting to 
the emergency department in the context of MA intoxication 
may be agitated, violent, or suicidal.21 Hydrogen 1 (1H) MR 
spectroscopy is complementary to MR imaging and adds 
clinically relevant information about metabolites in common 
brain abnormalities. Also, NAA levels may reflect 
mitochondrial (dys) function. Elevated mIns is generally 
considered a marker for gliosis. High tCho may be a marker for 
cellular proliferation, increased membrane turnover, or 
inflammation. Elevated Lac is indicative of anaerobic 
glycolysis and may be considered an unspecific MR 
spectroscopy biomarker for several abnormalities.22 
Conventional MR imaging is not able to depict changes in cell 
density, cell type, or biochemical composition—all of which 
can be investigated with MR spectroscopy.23 Furthermore, 
lesions of different underlying pathophysiology often manifest 
with a similar MR imaging appearance. Accordingly, MR 
imaging and MR spectroscopy are complementary tools for 
diagnosing disease and monitoring disease progression and 
response to therapy. MR imaging alone cannot provide the 
answer to many important clinical questions.24 These include 
differentiating tumor from other focal lesions (giant 
demyelinating plaques, encephalitis), obtaining a definitive 
diagnosis of atypical ring-enhancing focal lesions (i.e. high-
grade gliomas, metastasis, lymphoma, and abscess), identifying 
the optimal biopsy sites in heterogeneous gliomas, monitoring 
the response to treatment, and differentiating between 
treatment-induced changes and recurrent tumor.22,23,25 MR 
spectroscopy can provide information in all of these key 
clinical areas, and it is increasingly being used as an adjunct to 
MR imaging.21 
Materials and Methods  
Participants were selected from among healthy subjects 
without a history of cerebrovascular and psychiatric illnesses, 
as well as methamphetamine users with the help of Shahroud 
university of medical sciences drug abuse collaboration team, 
considering the entry conditions (table 1). Written consent was 
obtained from all participants before the study began. 
Proton MRS imaging (MRSI), the multivoxel version of 
MRS, and prescriptive structural MRI were acquired together 
in a single session. In addition to MRSI, scanning sequences 
included a localizer scout and a high-resolution T1-weighted 
whole-brain MRI. MRSI spectra of the dopamine circuit (VTA, 
NAc, Substantia nigra, Striatum, Frontal cortex, Hippocampus) 
acquired on a 1.5 T Siemens (Avanto, Imam Hossein hospital 
in Shahroud university of medical sciences) using standard 
head coil (18 channel) with the following parameters: High 
resolution T1 image (MPRAGE) measured with parameters 
(TR=1500, TE=1.53.3.21.4.89.6.57 ms) (FA=7) (FOV=256 
mm), cross-sectional thickness of 1 mm 160 slice and scan time 
of 10 minutes. Then 3DCSI imaging acquired with parameters 
TE=30, TR=1500, with NEX=2, FOV=160.160.160, 
VOI=100.50.80, sectional thickness equal to 15 mm. CHESS 
automatic pulse twice with two TE and two VOIs took place in 
15 minutes. Analysis using the console Siemens syngo 
software was done by measuring the curvature of the NAA, 
cho, Cr, mI, with two VOIs (including 5 anatomical regions) 
with two TE high and short, and after obtaining the 
corresponding curve. The spectrum of metabolites was 
presented to the radiologist with experience in the field of 
spectroscopy for interpretation (figure 1). 
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Table 1. Demographic data of participants and scores of PANSS in METH users group 
 Abstinent methamphetamine-dependent (n=30) Controls (n=10) 
Age (years) 35.0±15 35±15 
Gender (female/male) 10/20 5/5 
Total meth used (gr) 2±2  
Duration of abstinence 4±3  









Figurer 1. MRSI spectra extracted using spectroscopic evaluation software (syngo simens) and concentrations of metabolites were extracted in the regions of interest 
using statistical analysis 
 
For comparison of the mean values of the metabolite ratios 
between methamphetamine users and comparison subjects, the 
Student’s t -test was used. Correlations between the metabolite 
ratios and each of the clinical parameters, including the 
duration of methamphetamine use, duration of the abstinence, 
and panss score, were evaluated using Pearson’s correlation 
coefficient. Statistical significance was set at 0.05. We 
measured metabolite ratios in the dopamine circuit (ventral 
tegmental area, nucleus accumbens, substantia nigra, striatum, 
frontal cortex, and hippocampus). To avoid such errors, we 
used repeated measures analysis of variance (ANOVA) in 
which repeated measures were the left and right metabolite 
ratios. 
Results 
Statistical analysis revealed significant relationship between 
the mean concentration of brain metabolites in the studied areas 
and the incidence of psychological disorders between the control 
group and methamphetamine dependence group. 
Significant decrease in the concentration of NAA 
metabolites in the methamphetamine group with high 
psychological symptoms (Figurer 2) (PANSS) in the studied 
areas compared to the control group, which is a 
neurotransmitter and biomarker, indicates chronic neurological 
degeneration in the test areas and its relationship with the 
incidence of mental disorders in these individuals 
(Pvalue<0.01). Changes in the concentration of choline 
metabolite representing cell membrane changes are associated 
with a degree of mental disorder. There was also no significant 
correlation between Choline changes with dose and duration of 
use. (Pvalue<0.01). The amount of changes in the GLX 
metabolite, which represents changes in the level of 
neurotransmitters, has a positive correlation with the amount of 
psychiatric disorders (Pvalue<0.01). There is a relationship 
between the changes in the metabolism of mayoinozitol, which 
represents glial cells, and the incidence of the psychiatric 
disorders (Pvalue<0.01). Also, there was a positive relationship 
between the changes in keratin metabolism and the incidence 
of the psychiatric disorders. (Pvalue<0.01) (Table 2). 
Table 2. Pearson r correlations between Subscale PANSS scores and mean total metabolite concentration in five regions for participates (n=30) 
 Group N Mean Std. Deviation Sig. (2-tailed) 
NAA 
Abuser 30 18.5603 5.91551 .001 
Normal 10 25.5700 4.13415 .000 
Cr 
Abuser 30 14.1910 6.60855 .044 
Normal 10 9.7430 2.01238 .002 
cho 
Abuser 30 11.4377 3.73582 .008 
Normal 10 8.0250 1.12411 .000 
GLX 
Abuser 30 7.0790 2.85727 .000 
Normal 10 2.2870 1.14148 .000 
mI 
Abuser 30 7.3270 2.84909 .004 
Normal 10 4.4000 1.69837 .001 
PANSS 
Abuser 30 111.90 18.40418 .000 
Normal 10 23.9000 7.72370 .000 
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Figurer 2. Linear curve estimation of PANSS and metabolite concentration correlation 
 
Discussion 
The findings suggest that following the use of 
methamphetamine and the sustainability of this condition, 
nerve degradation processes (a decrease in the metabolism of 
NAAs) spread across the different regions of the brain, 
particularly serotonergic and dopaminergic regions. The 
severity and extent of this degradation is related to the 
incidence and severity of psychological symptoms and is 
clearly visible even in the early stages of the disorder.13 Also, 
changes in the level of other biochemical markers such as 
keratin and choline indicate neural toxicity and changes in cell 
membrane in the studied areas.10 The rate of changes in the 
marker mayoinozitol (mI) in the studied areas and its reduction, 
especially in the basal ganglia, also indicate the beginning of 
neurodegenerative processes and neuronal death.14 Also, 
changes in neurotransmitters that have been reported in 
positron release studies in previous studies have significantly 
shown changes in glutamate and glutamine levels as well as 
GABA, which is consistent with the results of our study.21 
Behavioral changes in mood and also the incidence of violent 
and pseudo-schizophrenic behaviors and adaptation of these 
pathological findings with the PANSS psychoanalysis test 
indicate the severity and extent of the disorders.14 
According to previous studies, patients with chronic METH 
psychosis who had been abstinent from METH for more than 1 
month qualitatively reported experienced visual hallucinations, 
delusions, and persecutory delusions, while all experienced 
auditory hallucinations. They found no difference in the 
patterns of delusions experienced between those with chronic 
METH psychosis and schizophrenia and that auditory 
hallucinations were the most common type of hallucination 
experienced between groups.12 Our findings also support this 
idea, there is a decrease in the level of NAA consistent with an 
increase in visual hallucinations and delusion in the meth 
dependence group. 
Another study described persistent METH psychosis and 
schizophrenia demonstrated comparable severity and frequency 
of positive symptoms, and both of these groups had PANNS 
scores that were significantly higher than those in the acute 
METH psychosis group.13 According to the results of PANSS 
Scales in our study, it was observed that the severity and 
frequency of positive symptoms were more strongly related to 
metabolite concentration than negative symptoms. Negative 
symptoms such as flat affect, social withdrawal, apathy, loss of 
drive, anhedonia, and poverty of speech have also been 
reported in METH psychosis samples.4 However, in our study, 
no significant relationship was found between these symptoms 
and study variables. 
The key role of the dopamine circuit (VTA, NAc, 
substantia nigra, striatum, PFC, hippocampus) and the 
mesocorticolimbic pathway in substance abuse has been proven 
in previous studies. However, the evaluation of all these areas 
together has received less attention. The Accumbens (NAc) has 
been implicated in numerous neurological and psychiatric 
disorders, including depression, obsessive-compulsive disorder, 
bipolar disorder, anxiety disorders, Parkinson’s disease, 
Alzheimer’s disease, Huntington’s disease, obesity, and drug 
abuse and addiction (Accumbens).24,25 The NAc has 
dopaminergic inputs from mesolimbic structures as well as 
prefrontal areas including the medial prefrontal cortex (MPFC) 
and anterior cingulate (ACC), which may be responsible for the 
NAc response to reward via pain relief. The NAc is 
functionally connected to ACC and MPFC at rest and 
coactivated with basal ganglia, ACC, and insula.10 Nucleus 
accumbens is a major input structure of the basal ganglia and 
integrates information from cortical and limbic structures to 
mediate goal-directed behaviors.11 
Chronic exposure to several classes of drugs of abuse 
disrupts plasticity in this region, allowing drug-associated cues 
to engender a pathologic motivation for drug seeking.9 The 
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NAc is a major component of the ventral striatum and has long 
been thought to be a key structure involved in mediating 
motivational and emotional processes, the limbic-motor 
interface, and the effects of certain psychoactive drugs. 
Overall, however, the NAc appears to be a key structure in 
the natural reward system, which includes modulation of 
motivation and incentivized learning.16 Coupled with 
connectional studies, these findings have led to the suggestion 
that the NAc plays a central role in a positive emotional 
response pathway, counterbalanced by a negative emotional 
response pathway mediated by the amygdala,13 although others 
believe the NAc itself may play a vital role in aversive 
motivation.18 
Synthesizing centers, as well as dopamine and serotonin 
action centers, which are both causes of pleasure and a good 
sense of humans in methamphetamine users, were identified as 
the main places of occurrence of these metabolic and 
biochemical disorders in this study, although changes in other 
areas and in multiple studies have been reported the main 
system for these disorders is double-headed and serotonin 
systems.21 
Methamphetamine use is associated with decreased 
neuronal integrity and viability, specifically dopamine circuit 
(ventral tegmental area, nucleus accumbens, substantia nigra, 
striatum, frontal cortex, and hippocampus). Methamphetamine 
dependence is associated with active neurodegeneration in the 
dopamine circuit, but this was not found in the control group, 
and in the chronic phase and the sustained nerve damage, it 
causes severe psychiatric disorders. MRS can be very helpful in 
detecting the progression of disease and degree of deterioration 
as well as follow-up treatment in patients with 
methamphetamine abuse. 
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